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In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3
histone, LASU1, and HectH9). ARF-BP1,
a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation
of ARF-BP1 stabilised p53 and induced apoptosis. Notably, inactivation of ARF-BP1 also caused cell growth repression in p53-null
cells and breast cancer cells with mutant p53. Thus, ARF-BP1 emerges as a novel therapeutic target against cancer regardless of p53
status.
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The function of p53 as a transcription factor in the induction of
cell growth arrest and apoptosis has been widely known and the
importance of its role in tumour suppression has been firmly
established. The activity of p53 as a sequence-specific transcription
factor is highly regulated by other proteins through post-
translational modifications, protein–protein interactions and
protein stabilisation (Brooks and Gu, 2003; Harris and Levine,
2005). Therefore, study of regulators of p53 becomes very
important in exploring cancer therapy (Bykov and Wiman, 2003;
Vassilev et al, 2004).
Until recently, Mdm2, a RING finger E3 ubiquitin ligase, was
thought to be the main regulator of p53 by ubiquitination and
subsequent degradation by the 26S proteasome (Oren, 2003;
Vousden and Prives, 2005). ARF (known as p14
ARF in humans and
p19
ARF in mouse) was originally identified as an alternative
transcript of the Ink4a/ARF tumour-suppressor locus (Sherr,
2004). ARF exhibits tumour-suppressor functions, as demon-
strated by the tumour susceptibility phenotype of p19
ARF-deficient
mice (Kamijo et al, 1997). The N-terminus region of ARF (N-ARF:
residues 1–64), encoded by the unique 1b exon, is critical for ARF-
mediated p53 activation as well as p53-independent ARF functions.
The C-terminal region (C-ARF: residues 65–132), which is not
conserved between human and mouse counterparts, is of uncertain
function. ARF directly binds to and inactivates Mdm2 resulting in
p53 stabilisation and p53-dependent apoptosis or cell cycle arrest
(Quelle et al, 1995; Zhang et al, 1998). The ARF-Mdm2-p53 axis is
undoubtedly an important component of ARF’s tumour-suppres-
sor activity. However, a number of recent studies have demon-
strated that ARF also possesses p53- and Mdm2- independent
functions. For example, ARF can induce cell growth arrest in
tumour cells that lack a functional p53 gene or its key
transcriptional target p21 (Weber et al, 2000; Modestou et al,
2001; Korgaonkar et al, 2002; Eymin et al, 2003; Normand et al,
2005). Expression of ARF inhibits the proliferation of cells that are
null for both p53 and Mdm2 (Weber et al, 2000). Moreover, mice
lacking both ARF and p53 develop multiple primary tumours of a
wider spectrum than those mice lacking either gene alone. In the
same study, mice lacking p53, Mdm2, ARF were found to develop
tumours at a higher frequency and of wider spectrum than those
with mice lacking p53 and Mdm2 (Weber et al, 2000). Inactivation
of ARF by hypermethylation was observed in human colorectal
tumours having inactivated p53 (Esteller et al, 2001). Hence, ARF
targets other proteins in addition to Mdm2. Recently, it has been
reported that ARF interacts with B23 (nucleophosmin), a nucleolar
protein implicated in ribosomal biogenesis (Bertwistle et al, 2004).
Moreover, ARF has been shown to associate with c-Myc and
inhibit the expression of c-Myc-activated genes (Qi et al, 2004).
Interestingly, ARF interacts with certain members of the E2F
family of transcription factors (Martelli et al, 2001). All of these
might in part explain the p53-independent function of ARF, but
the mechanisms remain unclear.
ARF-BP1, A HECT E3 UBIQUITIN LIGASE, PLAYS AN
IMPORTANT ROLE IN THE MEDIATION OF P53
DEPENDENT AND INDEPENDENT EFFECTS ON ARF
In a recent study, a major protein band of B500kDa (named ARF-
BP1) was purified from HA-ARF-Flag-expressing H1299 cells by
mass spectrometric analysis (Chen et al, 2005). The C-terminal
sequences of ARF-BP1 (also known as Mule, UREB1, E3
histone,
LASU1 and HectH9) possess a HECT domain (4036–4374)
(Adhikary et al, 2005; Chen et al, 2005; Liu et al, 2005; Zhong
et al, 2005). ARF-BP1 also contains the ubiquitin-associated
domain (UBA, 1318–54) and a WWE domain (1612–92). The
former is a small sequence motif found in various proteins linked
to the ubiquitination pathway such as the DNA repair protein
Rad23 and the Cbl ubiquitin ligase. The latter may be involved in
protein–protein interactions. ARF-BP1 mRNA is broadly ex-
pressed in various types of human tissue (Chen et al, 2005).
A region of ARF-BP1 (1015–4574) not including the N-terminus
(1–1014) strongly bound the N-terminal domain of ARF. ARF and
ARF-BP1 also interact with each other under physiological
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lysates with a-ARF-BP1 or a-ARF (Chen et al, 2005). ARF-BP1
displays E3 enzymatic activity in an in vitro assay, and this self-
ubiquitination activity was strongly repressed by ARF (Chen et al,
2005). Notably, ARF-BP1 inactivation by RNAi induces cell growth
repression with G2/M arrest in p53-null cells H1299 and Saos-2,
similar to that seen in response to ARF induction (Eymin et al,
2003; Chen et al, 2005; Normand et al, 2005). Based on our
observation that ARF-BP1 is the major binding partner of ARF in
p53-null cells, the ability of ARF to neutralise ARF-BP1 plays a
critical contribution to the p53-independent antiproliferative
effects of ARF (Chen et al, 2005; Shmueli and Oren, 2005). Future
work is necessary to clarify the precise mechanism of ARF-BP1-
mediated and p53-independent cell growth inhibition induced by
ARF. As ARF-BP1 is a bona fide E3 ubiquitin ligase, it is likely that
the p53-independent functions of ARF involve unidentified
enzymatic substrates of ARF-BP1.
Surprisingly, ARF-BP1 can interact directly with the p53 protein
and induces p53 ubiquitination. Significantly, ARF-BP1-mediated
p53 ubiquitination was strongly repressed by ARF (Chen et al,
2005). Also, the N-terminal region of ARF retained full inhibition
of ARF-BP1-mediated p53 ubiquitination whereas the C-terminal
region showed no effect. This is consistent with the previous
reports that N-terminal ARF has full functional responses (Weber
et al, 1999; Midgley et al, 2000). RNAi-mediated knockdown of
ARF-BP1 stabilised p53 and induced apoptosis (32.3%) in human
osteosarcoma cells (U2OS). Similar results were achieved using
different cell lines with wild-type p53, such as human breast
carcinoma cells (MCF-7), human lung adenocarcinoma cells
(A549) and normal human fibroblast cells (NHF-1) (Chen et al,
2005). An inverse correlation between ARF-BP1 and p53 expres-
sion in colorectal carcinoma samples has also been shown by
immunofluorescence (Yoon et al, 2005). By overexpression, ARF
can stabilise p53 in p53/Mdm2 double-null MEF cells. Moreover,
the p53 stabilisation induced by ARF was clearly attenuated by
further ARF-BP1 knockdown of these cells, suggesting that ARF-
BP1 is critical for ARF-mediated p53 stabilisation in an Mdm2-
independent manner (Chen et al, 2005).
In addition, two other recently identified proteins, Pirh2 and
COP1, are also found to promote p53 degradation via the
ubiquitin-proteasome pathway (Leng et al, 2003; Corcoran et al,
2004; Dornan et al, 2004). We tested the differential effects of the
known E3 ligases on p53 stabilisation by RNAi knockdown (Chen
et al, 2005). Depletion of Mdm2 stabilised p53 while depletion of
either COP1 or Pirh2 had a modest effect. Remarkably, inactiva-
tion of ARF-BP1 strongly induced p53 stabilisation and activated
p53-mediated transcription; among the known E3 ligases for p53,
ARF-BP1 RNAi induced the highest levels of p21 and Bax, and
exhibited similar effects to ARF overexpression. Hence, ARF-BP1
is a major E3 ubiquitin ligase for p53, and more importantly, is
also a key mediator for ARF tumour-suppressor function.
It is now clear that ARF interacts with and regulates at least two
distinct E3 ubiquitin ligases, Mdm2 and ARF-BP1, for their
ubiquitination of p53 (den Besten et al, 2005). This is consistent
with the previous evidence suggesting that ARF-mediated activa-
tion of p53 is more complicated than the simple ARF-Mdm2-p53
model. First, while the low levels of Mdm2 that are commonly
observed in normal cells preferentially catalyse monoubiquitina-
tion of p53 (Li et al, 2003), ARF can not inhibit Mdm2-mediated
monoubiquitination of p53 in vivo, although it can block p53
polyubiquitination (Xirodimas et al, 2001). Second, recent studies
of p19
ARF demonstrated that ARF is able to cause cell cycle arrest
independent of Mdm2 relocalisation to nucleoli and p53 stabilisa-
tion (Llanos et al, 2001; Korgaonkar et al, 2002). Thus, a critical
question raised is how ARF can efficiently stabilise p53 in normal
cells with low levels of Mdm2, a situation where Mdm2 is not solely
responsible for p53 degradation. Our results with ARF-BP1 suggest
a novel pathway independent of Mdm2 for ARF-mediated p53
activation. ARF-BP1 was identified as a significant component of
ARF-containing protein complexes and endogenous protein
interaction between ARF-BP1 and ARF is easily detected in
unstressed cells. These two distinct pathways for ARF-mediated
p53 activation allow for more precise control of p53, but also raise
the question of their biological significance. For example, it is well
established that Mdm2 plays a critical role in tumorigenesis.
Protein overexpression and gene amplification of Mdm2 are found
in various types of tumours (Michael and Oren, 2003). Thus, the
ARF-Mdm2 pathway might be especially important in cells
expressing high levels of Mdm2. Interestingly, we found that
ARF-BP1 is highly expressed in 80% (16 out of 20) of breast cancer
cell lines while the expression level of ARF-BP1 in normal breast
cells (MCF-10A) is low, suggesting a potential role of ARF-BP1 in
breast cancer tumorigenesis.
The importance of p53 in cancer development is illustrated by
the fact that p53 is highly mutated in many different cancers. The
mutations are found mainly in the specific DNA-binding core
domain of p53-residues 98–292 (Soussi and Lozano, 2005). It may
be interesting to deduce the functional consequence of ARF-BP1
reduction in cells expressing mutant p53. Significantly, inactiva-
tion of ARF-BP1 could also inhibit cell growth in cancer cells with
mutant p53 (MDA-MB-468, Hs-578t) (Figure 1). Similar results
were also found in other breast cancer cells with mutant p53 such
as T47D, BT-549, MDA-MB-435, SK-BR-3.
ADDITIONAL TARGETS OF ARF-BP1/HectH9
It was recently reported that ARF-BP1 ubiquitinated Myc through
a lysine 63-linked polyubiquitin chain (Adhikary et al, 2005). This
ubiquitation does not cause Myc degradation (Adhikary et al,
2005), consistent with the absence of Myc stabilisation when ARF-
BP1 is inactivated (Chen et al, 2005). However, the ubiquitination
of Myc by ARF-BP1 significantly alters transcription properties of
Myc. Depletion of ARF-BP1 downregulates Myc-dependent gene
activation and represses cell proliferation induced by Myc.
Similarly, depletion of ARF-BP1 by RNAi leads to growth arrest
in HeLa cells, despite a high endogenous level of Myc expression
(Adhikary et al, 2005). Thus, it appears that ARF-BP1 functionally
MDA-MB-468
(p53: R273H)
Hs-578t
(p53: V157F)
Control RNAi ARF-BP1 RNAi
Figure 1 Inactivation of ARF-BP1 induces cell growth repression of
breast cancer cell lines (MDA-MB-468, Hs-578t) with mutant p53. The
breast cancer cells (MDA-MB-468 or Hs-578t) were stained with crystal
violet 3 days after three rounds treatment with either control or ARF-BP1
RNAi.
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complex since ARF and Myc bind each other directly (Qi et al,
2004). It is reasonable that the inhibition of ARF-BP1 by ARF could
contribute at least in part to ARF-mediated inhibition of Myc
transcriptional activation, although it has not been established yet
that ARF inhibits Myc ubiquitination mediated by ARF-BP1. Myc
seems to be one of the ARF-BP1 p53-independent substrates. The
induction of ARF by Myc may serve as a negative feedback loop to
limit excessive Myc function (Figure 2). High expression of ARF-
BP1 may disrupt this feedback loop and is essential for
tumorigenesis. ARF-BP1/HectH9 is indeed overexpressed in a
variety of primary tumour samples (Adhikary et al, 2005; Yoon
et al, 2005). In addition, ARF-BP1/Mule recently was reported to
ubiquitinate and degrade the anti-apoptotic protein Mcl-1 (Warr
et al, 2005; Zhong et al, 2005). The physiologic consequences of
degrading both proapoptotic and antiapoptotic proteins remain
unclear, although it is possible that ARF-BP1 differentially targets
these proteins under different states of cell stress and/or other
physiologic conditions. These other targets may somehow limit the
therapeutic potential of ARF-BP1 in cancer therapy. In the future,
it will be important to ascertain specific circumstances in which
proteins like MCl-1 are activated, so that these situations can be
avoided in treatments targeting the ARF-BP1-p53/myc pathway.
Moreover, future work is necessary to uncover additional
molecular substrates of ARF-BP1 as suggested by its large size
(Shmueli and Oren, 2005).
ARF-BP1 AS A THERAPEUTIC POTENTIAL
FOR CANCER
Recently, numerous studies indicate that activating p53 is very
important for the function of many cancer therapy drugs in vivo;
p53-dependent apoptosis seems to have a major role for the
efficiency of cancer chemotherapy in cancer cells expressing wild
type p53. The negative regulation of p53 by ARF-BP1 has now been
established (Gu et al, 1995; Chen et al, 2005). Based on our results
that inactivation of ARF-BP1 expression activates p53 function,
ARF-BP1-mediated negative regulation of p53 might be a very
important target for cancer therapy. Thus, potential drugs that can
downregulate ARF-BP1 protein levels or abrogate the ARF-BP1-
p53 interaction in vivo may sensitise tumour cells. Similarly,
agents that activate the p53 tumour-suppression pathway, includ-
ing Nutlin and HLI98, small molecules that block the p53-Mdm2
interaction (Vassilev et al, 2004), and inhibit the E3 ubiquitin
ligase activity of Mdm2, respectively, (Yang et al, 2005) are
currently being tested for their potential use in cancer therapy.
However, the utility of these agents is limited to tumours that
maintain a functional p53 pathway, a significant restriction given
that p53 is often inactivated by mutations. Since inactivation of
ARF-BP1 could also induce growth arrest in p53-null or mutant
p53 cells, at least partially through downregulation of Myc-target
genes, inhibitors of ARF-BP1 should suppress tumour cell growth
in a wide spectrum of tumour types. Therefore, ARF-BP1 may
prove to be an especially valuable therapeutic target for a wider
variety of cancer types.
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